Taysha Gene Therapies, Inc. SEC filings TSHA
Taysha Gene Therapies, Inc. has 401 filings in SEC EDGAR's recent list, going back to May 4, 2020. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Jun 25, 2026 | — |
| 424B5 | Prospectus supplement | Jun 24, 2026 | — |
| S-8 | Employee stock plan registration | Jan 6, 2026 | — |
| S-3ASR | Automatic shelf registration | Nov 4, 2025 | — |
| 424B5 | Prospectus supplement | May 29, 2025 | — |
| 424B5 | Prospectus supplement | May 28, 2025 | — |
| S-8 | Employee stock plan registration | Jan 7, 2025 | — |
| S-3 | Shelf registration | Dec 13, 2024 | — |
| 424B5 | Prospectus supplement | Jun 26, 2024 | — |
| 424B5 | Prospectus supplement | Jun 26, 2024 | — |
| S-8 | Employee stock plan registration | Mar 19, 2024 | — |
| S-8 | Employee stock plan registration | Dec 20, 2023 | — |
| 424B3 | Prospectus | Sep 11, 2023 | — |
| S-3 | Shelf registration | Aug 30, 2023 | — |
| 424B3 | Prospectus | May 4, 2023 | — |
| S-3 | Shelf registration | Apr 5, 2023 | — |
| 424B5 | Prospectus supplement | Mar 29, 2023 | — |
| S-8 | Employee stock plan registration | Mar 28, 2023 | — |
| 424B5 | Prospectus supplement | Oct 27, 2022 | — |
| 424B5 | Prospectus supplement | Oct 25, 2022 | — |
| 424B5 | Prospectus supplement | Mar 31, 2022 | — |
| S-8 | Employee stock plan registration | Mar 31, 2022 | — |
| S-3 | Shelf registration | Oct 5, 2021 | — |
| S-8 | Employee stock plan registration | May 11, 2021 | — |
| S-8 | Employee stock plan registration | Sep 29, 2020 | — |
| 424B4 | Prospectus | Sep 25, 2020 | — |
| S-1MEF | Filing | Sep 23, 2020 | — |
| S-1/A | Amended registration statement | Sep 18, 2020 | — |
| S-1/A | Amended registration statement | Sep 17, 2020 | — |
| S-1/A | Amended registration statement | Sep 8, 2020 | — |
| S-1 | Registration statement | Sep 2, 2020 | — |
Showing 31 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TSHA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Dallas, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1806310
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.